Daiichi Sankyo Espha Receives Manufacturing and Marketing License in Japan for “Levofloxacin Tablets 250mg/500mg” and “Granules 10% DSEP”

Daiichi Sankyo's picture
Printer-friendly versionPrinter-friendly version

Tokyo, Japan (September 1, 2014) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its domestic generic drug subsidiary, Daiichi Sankyo Espha Co., Ltd. (hereafter Daiichi Sankyo Espha), obtained a manufacturing and marketing license in Japan on August 15, 2014 for Levofloxacin Tablets 250mg DSEP, 500mg DSEP and Granules 10% DSEP (hereafter Levofloxacin).


Levofloxacin is an authorized generic drug manufactured from the same substance and additives and using the same manufacturing methods and in the same location as Daiichi Sankyo’s synthetic broad-spectrum oral antibacterial agent “Cravit® Tablets, Granules” (generic name: Levofloxacin hydrate; hereafter, Cravit), which is already available.


Daiichi Sankyo Espha plans to release Levofloxacin once it is listed on the drug price list, working together with Daiichi Sankyo to meet the needs of patients and medical professionals by promoting the appropriate use of antibacterial drugs.


During the period before the drug price listing, Daiichi Sankyo will continue to make every effort to keep medical professionals informed of the efficacy and safety of Cravit, based on usage results acquired up to now.


Following the spirit of its corporate philosophy, “To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs,” Daiichi Sankyo is continually striving to meet medical needs and provide new treatment options.

Copy this html code to your website/blog to embed this press release.


Post new comment

4 + 11 =

To prevent automated spam submissions leave this field empty.
Page execution time was 5919.67 ms.

Memory usage:

Memory used at: devel_init()=2.13 MB, devel_shutdown()=22.55 MB.